Status:
COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia
Lead Sponsor:
Sadat City University
Conditions:
Schizophrenia
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
PHASE2
Brief Summary
The aim of this study to evaluate the efficacy and safety of pentoxifylline, the novel phosphodiesterase inhibitor, as an adjunctive to risperidone in alleviating the negative symptoms of schizophreni...
Detailed Description
there is some evidence for the role of phosphodiesterase (PDE) signaling system in pathophysiology of schizophrenia making this system a potential target for therapeutic agents. PDEs are a family of e...
Eligibility Criteria
Inclusion
- Ages between 18-40 years
- Males \& females
- patients between the ages of 18 and 53 who met the diagnostic criteria for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (20), with a minimum disease duration of two years.
- stable on risperidone for a minimum of 8 weeks
- clinically stable for at least 4 weeks prior to study.
- willing to give informed consent.
- able to take medication orally.
Exclusion
- Acute, unstable, significant or untreated medical illness beside schizophrenia;
- Pregnant or breast-feeding females;
- History of substance abuse or dependence in the past 3 months.
- Known contraindication to pentoxifylline treatment.
- Any serious or life-threatening medical conditions or neurological problem, severe extrapyramidal symptoms, history of abnormal bleeding, presence of hypothyroidism, renal disease, cardiovascular problems, rising liver transaminases to 3 times the upper limit of normal or higher
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04094207
Start Date
January 1 2019
End Date
September 30 2022
Last Update
October 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine
Shibīn al Kawm, Egypt